+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


US Veterinary Oncology Market Size, Share & Trends Analysis Report by Therapy (Surgery, Radiology, Chemotherapy, Immunotherapy), Animal Type (Canine, Feline), and Segment Forecasts, 2021-2028

  • ID: 5351633
  • Report
  • June 2021
  • Region: United States
  • 110 pages
  • Grand View Research
The U.S. veterinary oncology market size is expected to reach USD 143.2 million by 2028. The market is expected to expand at a CAGR of 8.4% from 2021 to 2028. The increasing prevalence of cancer in pets, willingness to spend on them by pet owners, and use of canine as a model for clinical trials by researchers are the key contributing factor towards this segment growth. In addition, an increase in the incidence of cancer in the feline population and rising pet ownership resulting in the increased focus on pet health is further expected to spur the growth.

Moreover, companies operating in the market are increasingly adopting strategies, such as mergers and acquisitions, research agreements, collaboration, partnerships, geographic expansion, and product development to enhance their position in the market. For instance, in November 2020, Virbac publicized the approval of Stelfonta, a novel intratumoral injection treatment for canine mast cell tumors. In addition, Elanco purchased Aratana Therapeutics for its pet products pipeline. The company also had an agreement to create rabacfosadine (Tanovea), a drug from VetDC. The drug also had received U.S. FDA approval for treating lymphoma in dogs. Hence, the market is expected to witness intense competition over the forecast period.

Clinical trials are a critical aspect of veterinary oncology. The accelerated number of clinical research involving surgical procedures in pets is further fueling the market growth. For instance, in May 2019, Oregon State University conducted a research study stating that the risk of cancer recurrence reduced to 60% in dogs whose tumors were completely resected. With the growing number of pet parents in the U.S., animal health awareness is rising amongst people. In the U.S. there are various pet health awareness events such as National Pet Week are conducted to create awareness.

The risk of animals spreading COVID-19 to individuals is considered to be little. The FDA is alert that the COVID-19 pandemic may influence ongoing studies being conducted to provision new animal drug development. Thereby, issued guidelines in April 2020 to help to diminish the potential impact of the pandemic on new animal drug development.

U.S. Veterinary Oncology Market Report Highlights

  • The radiology segment is expected to dominate the market. Factors such as increasing government initiatives to the establishment of new veterinary radiation centers and advancements in radiation technology are expected to boost demand for the radiation therapy segment
  • The immunotherapy segment is expected to witness a CAGR of 8.9% owing to the growing number of veterinary centers focused on carrying out clinical trials in immunotherapy areas
  • The chemotherapy segment is the second-largest segment of the market. According to Cancer Veterinary Center, the most common canine and feline tumors treated with chemotherapy are osteosarcomas, lymphomas, hemangiosarcoma, mast cell tumors, bladder tumors, and mammary gland tumors
  • The canine segment emerged as the largest revenue-generating segment of the market in 2020. The rising incidence of cancer in canines and ongoing product innovations in this domain is the key growth contributors
Note: Product cover images may vary from those shown
Chapter 1 Research Methodology & Scope
1.1 Market Segmentation & Scope
1.2 Research Methodology
1.3 Information Procurement
1.4 Information or Data Analysis
1.5 Market Formulation & Validation
1.6 Model Details
1.7 List of Secondary Sources
1.8 List of Primary Sources
1.9 Abbreviations
1.10 Report Objectives

Chapter 2 Executive Summary
2.1 Market Outlook
2.2 U.S. Veterinary Oncology Market Summary, 2020
2.3 Segment Outlook

Chapter 3 Veterinary Oncology Market Variables Trends & Scope
3.1 Market Lineage Outlook
3.2 Penetration & Growth Prospect Mapping by Technology, 2020
3.3 U.S. Veterinary Oncology Market Dynamics
3.4 Industry Analysis - Porter’s
3.5 U.S. Veterinary Oncology - SWOT Analysis, by Factor (Political & Legal, Economic, Social and Technological)
3.6 User Perspective Analysis
3.7 Regulatory Framework
3.8 Technology Overview
3.9 Product Pipeline Analysis
3.10 Pricing Trend Analysis

Chapter 4 COVID-19 Impact
4.1 Covid-19 Prevalence
4.2 Impact of COVID-19 on the Market
4.3 Regulatory/Policy Changes
4.4 Strategies Adopted by Market Players

Chapter 5 Competitive Analysis
5.1 Market Participation Categorization
5.2 Competitive Analysis
5.3 Market Entry Strategies

Chapter 6 U.S. Veterinary Oncology Market: Therapy Estimates & Trend Analysis
6.1 Therapy Market Share Analysis, 2020 & 2028
6.2 Therapy Dashboard
6.3 Surgery
6.4 Radiology
6.5 Chemotherapy
6.6 Immunotherapy
6.7 Others

Chapter 7 U.S. Veterinary Oncology Market: Animal Type Estimates & Trend Analysis
7.1 Animal Type Market Share Analysis, 2020 & 2028
7.2 Animal Type Dashboard
7.3 Canine
7.4 Feline
7.5 Others

Chapter 8 Company Profiles
8.1 Zoetis
8.2 Boehringer Ingelheim GmbH
8.3 Elanco
8.4 PetCure Oncology
8.5 Accuray Incorporated
8.6 Varian Medical Systems, Inc.
8.7 Morphogenesis, Inc.
8.8 Karyopharm Therapeutics, Inc.
8.9 Regeneus Ltd.
8.10 OHC (One Health Company)
8.11 List of Market Participants

List of Tables
Table 1. List of secondary sources
Table 2. List of abbreviation
Table 3. U.S. Pet Ownership, 2019-2020 (millions)
Table 4. U.S. Pet Expenditure, 2019-2020 (USD)
Table 5. Clinical Trials in progress for companion animals by UC Davis in 2018
Table 6. U.S. Veterinary Oncology Market, 2016-2028 (USD Million)
Table 7. U.S. Veterinary Oncology Market, by therapy, 2016-2028 (USD Million)
Table 8. U.S. Veterinary radiology Market, by type, 2016-2028 (USD Million)
Table 9. U.S. Veterinary stereotactic radiation therapy Market, by type, 2016-2028 (USD Million)
Table 10. U.S. Veterinary Oncology Market, by animal type, 2016-2028 (USD Million)
Table 11. U.S. feline oncology Market by cancer type, 2016-2028 (USD Million)
Table 12. U.S. canine oncology Market by cancer type, 2016-2028 (USD Million)

List of Figures
Fig. 1 Market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Target Population & Treatment Rate
Fig. 10 Treatment Cost analysis
Fig. 11 Commodity flow analysis
Fig. 12 U.S. Veterinary Oncology market revenue (USD Million)
Fig. 13 U.S. Veterinary Oncology Market Snapshot
Fig. 14 Segment Outlook, 2020
Fig. 15 Parent market outlook
Fig. 16 Ancillary market outlook
Fig. 17 Penetration &growth prospect mapping by Technology, 2020
Fig. 18 U.S. Veterinary Oncology market dynamics
Fig. 19 U.S. Veterinary Oncology market driver impact
Fig. 20 Total pet expenditure in the U.S., 2010-2019, Billion
Fig. 21 Estimated pet population in the U.S., 2015-2019, Million
Fig. 22 U.S. Veterinary Oncology market restraint impact
Fig. 23 Consumer behavior analysis
Fig. 24 Market influencing analysis
Fig. 25 Technology timeline analysis
Fig. 26 Covid-19 prevalence
Fig. 27 Market participant categorization
Fig. 28 Veterinary oncology company market position analysis
Fig. 29 Market entry strategies
Fig. 30 U.S. Veterinary Oncology market: Therapy movement analysis
Fig. 31 U.S. Veterinary Oncology Market: Therapy Dashboard
Fig. 32 Surgery market, 2016-2028 (USD Million)
Fig. 33 Radiology market, 2016- 2028 (USD Million)
Fig. 34 Veterinary Stereotactic radiation therapy market, 2016-2028 (USD Mullion)
Fig. 35 Gamma knife market revenues, 2016-2028 (USD Million) )
Fig. 36 LINAC market revenues, 2016-2028 (USD Million)
Fig. 37 PBRT market revenues, 2016-2028 (USD Million)
Fig. 38 CyberKnife market revenues, 2016-2028 (USD Million)
Fig. 39 Brachytherapy market, 2016-2028 (USD Mullion)
Fig. 40 Others market, 2016-2028 (USD Mullion)
Fig. 41 Chemotherapy market, 2016- 2028 (USD Million)
Fig. 42 Immunotherapy market, 2016- 2028 (USD Million)
Fig. 43 Others market, 2016- 2028 (USD Million)
Fig. 44 U.S. Veterinary Oncology market: Animal Type movement analysis
Fig. 45 U.S. Veterinary Oncology Market: Animal Type Dashboard
Fig. 46 Canine market, 2016-2028 (USD Million)
Fig. 47 Lymphoma market, 2016-2028 (USD Million)
Fig. 48 Mast cell cancer market, 2016- 2028 (USD Million)
Fig. 49 Mammary and squamous cell cancer market, 2016-2028 (USD Million)
Fig. 50 Others market, 2016-2028 (USD Million)
Fig. 51 Feline market, 2016-2028 (USD Million)
Fig. 52 Mammary and squamous cell cancer market, 2016-2028 (USD Million)
Fig. 53 Others market, 2016-2028 (USD Million)
Fig. 54 Others market, 2016-2028 (USD Million)
Note: Product cover images may vary from those shown
  • Zoetis
  • Boehringer Ingelheim GmbH
  • Elanco
  • PetCure Oncology
  • Accuray Incorporated
  • Varian Medical Systems, Inc.
  • Morphogenesis, Inc.
  • Karyopharm Therapeutics, Inc.
  • Regeneus Ltd.
  • OHC (One Health Company)
Note: Product cover images may vary from those shown